EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-κB signalling activation independent of hydroxylase activity.
Fenglin CaiXiuding YangGang MaPengliang WangMengmeng ZhangNannan ZhangRupeng ZhangHan LiangYongzhan NieCheng DongJingyu DengPublished in: British journal of cancer (2024)
EGLN3 has the potential to hinder the spread of GC cells through a nonenzymatic mechanism, thereby shedding light on the complex nature of GC progression.